A phase I study of Cannabidiol/tetrahydrocannabinol (MedChew-1504) for the treatment of Restless Leg's Syndrome

Trial Profile

A phase I study of Cannabidiol/tetrahydrocannabinol (MedChew-1504) for the treatment of Restless Leg's Syndrome

Recruiting
Phase of Trial: Phase I

Latest Information Update: 11 Nov 2016

At a glance

  • Drugs Nabiximols (Primary)
  • Indications Restless legs syndrome
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 11 Nov 2016 The profile has been written from Axim Biotech product pipeline. (http://aximbiotech.com/product-timeline/)
    • 11 Nov 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top